Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

LCTXLCTX
Showing 7 of 27 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in LINEAGE CELL THERAPEUTICS IN

CITADEL ADVISORS LLC holds 426,169 shares of LCTX (LINEAGE CELL THERAPEUTICS IN), worth $558,282 as of 2026-Q2. The position was increased (+225.4% shares). LCTX represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$558,282

Current Shares

426,169

Total Value Change

+$492,065

Total Shares Change

+294,394

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
426,169
+225.4%
$558,2820.0%$1.31
39
2026-Q1
Decreased
130,948
-74.2%
$206,8980.0%$1.89
0
2025-Q4
Increased
507,052
+161.4%
$846,7770.0%$1.60
40
2025-Q3
Increased
193,968
+4.6%
$327,8060.0%$1.79
17
2025-Q2
Increased
185,481
+283.4%
$168,3060.0%$0.94
25
2025-Q1
Decreased
48,372
-63.3%
$21,8450.0%$0.49
0
2024-Q4
New
131,775
-
$66,2170.0%$0.50
32

Other major holders of LCTX: BlackRock, Inc., VANGUARD GROUP INC, VANGUARD CAPITAL MANAGEMENT LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used